-+ 0.00%
-+ 0.00%
-+ 0.00%

NOVOCURE’S OPTUNE LUA® RECEIVES CE MARK APPROVAL FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER

Reuters·04/22/2025 11:09:00

Please log in to view news